CY1117004T1 - Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτου - Google Patents
Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτουInfo
- Publication number
- CY1117004T1 CY1117004T1 CY20151101112T CY151101112T CY1117004T1 CY 1117004 T1 CY1117004 T1 CY 1117004T1 CY 20151101112 T CY20151101112 T CY 20151101112T CY 151101112 T CY151101112 T CY 151101112T CY 1117004 T1 CY1117004 T1 CY 1117004T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tetrahydroisoquinolin
- receptor
- derivative
- ibs
- therapeutic agent
- Prior art date
Links
- NTNKZGHUNBWBBV-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-2h-isoquinolin-1-one Chemical class C1C=CC=C2C(=O)NCCC21 NTNKZGHUNBWBBV-UHFFFAOYSA-N 0.000 abstract 3
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002550 fecal effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
[ΠΡΟΒΛΗΜΑΤΑ] Να παρασχεθεί μια ένωση η οποία να μπορεί να χρησιμοποιηθεί ως ένας φαρμακευτικός παράγων, ειδικότερα δε ένας θεραπευτικός παράγων για σύνδρομο ευερέθιστων εντέρων (IBS). [ΜΕΣΑ ΓΙΑ ΤΗΝ ΕΠΙΛΥΣΗ ΤΩΝ ΠΡΟΒΛΗΜΑΤΩΝ] Ανευρίσκεται ότι ένα παράγωγο τετραϊδροϊσοκινολιν-1-όνης έχοντας μια ομάδα αμιδίου στην θέση-4 ή ένα φαρμακευτικώς αποδεκτό άλας εξ' αυτού έχει μια εξαιρετική ανταγωνιστική δραστηριότητα σε έναν υποδοχέα βομβεσίνης-2 (ΒΒ2). Ανευρίσκεται επίσης ότι και το παράγωγο τετραΐδροϊσοκινολιν-1-όνης είναι κατ' εξοχήν αποτελεσματικό και σε μη-φυσιολογικό εύρημα κοπράνων. Επομένως, το παράγωγο τετραϊδροϊσοκινολιν-1-όνης είναι χρήσιμο ως ένας θεραπευτικός παράγων για μια πάθηση που συσχετίζεται με έναν υποδοχέα της ΒΒ2, ειδικότερα δε του IBS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007140097 | 2007-05-28 | ||
EP08764654.3A EP2149561B1 (en) | 2007-05-28 | 2008-05-26 | Tetrahydroisoquinolin-1-one derivative or salt thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117004T1 true CY1117004T1 (el) | 2017-04-05 |
Family
ID=40075016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151101112T CY1117004T1 (el) | 2007-05-28 | 2015-12-08 | Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτου |
Country Status (23)
Country | Link |
---|---|
US (5) | US8486970B2 (el) |
EP (1) | EP2149561B1 (el) |
JP (1) | JP5336359B2 (el) |
KR (3) | KR101830566B1 (el) |
CN (1) | CN101668747B (el) |
AU (1) | AU2008255815B2 (el) |
BR (1) | BRPI0812359A2 (el) |
CA (1) | CA2688326C (el) |
CY (1) | CY1117004T1 (el) |
DK (1) | DK2149561T3 (el) |
ES (1) | ES2558677T3 (el) |
HR (1) | HRP20151336T1 (el) |
HU (1) | HUE026316T2 (el) |
IL (1) | IL202301A (el) |
MX (1) | MX2009012779A (el) |
PL (1) | PL2149561T3 (el) |
PT (1) | PT2149561E (el) |
RS (1) | RS54429B1 (el) |
RU (1) | RU2479578C2 (el) |
SI (1) | SI2149561T1 (el) |
TW (1) | TWI425945B (el) |
WO (1) | WO2008146774A1 (el) |
ZA (1) | ZA200908220B (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011029832A1 (de) | 2009-09-09 | 2011-03-17 | Vifor (International) Ag | Neue thiazol- und oxazol-hepcidin-antagonisten |
CN107109701B (zh) * | 2014-09-16 | 2020-10-09 | 斯坦福国际研究院 | 通过光纤阵列扫描技术发现亲和试剂和催化剂 |
JP2019508496A (ja) * | 2016-02-15 | 2019-03-28 | チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の治療法のためのtaf1阻害剤 |
EP3490980A4 (en) * | 2016-07-22 | 2020-04-15 | Virginia Commonwealth University | PRODRUG AND PROTECTED FORMS OF 5-HYDROXYMETHYLFURFURANAL (5-HMF) AND ITS DERIVATIVES |
EP3768266A4 (en) * | 2018-03-20 | 2021-12-22 | Merck Sharp & Dohme Corp. | OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING PROTEIN INHIBITORS |
CN110563687B (zh) * | 2019-07-23 | 2022-09-30 | 上海合全医药有限公司 | 一种4-(氨基甲基)色烷-3-醇的制备方法 |
EP4074314A1 (en) * | 2021-04-15 | 2022-10-19 | Valdospan GmbH | Isoquinoline derivatives for use as antiviral and antitumour agents |
CA3214899A1 (en) | 2021-04-15 | 2022-10-20 | Lutz Weber | Isoquinoline derivatives for use as antiviral and antitumour agents |
CN113603625B (zh) * | 2021-08-12 | 2023-03-10 | 南京卓康医药科技有限公司 | 一种酮咯酸中间体的合成方法 |
WO2024083802A1 (en) | 2022-10-17 | 2024-04-25 | Valdospan Gmbh | Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL110172A (en) * | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicycle compounds and pharmaceuticals containing them |
EP1155001A4 (en) | 1999-02-22 | 2003-05-28 | Lion Bioscience Ag | ISOQUINOLEIN DERIVATIVES AND COMBINATORIAL ISOQUINOLEIN BANKS |
WO2001047891A1 (fr) * | 1999-12-28 | 2001-07-05 | Eisai Co., Ltd. | Composes heterocylciques contenant des groupes de sulfamide |
ES2572332T3 (es) * | 2000-10-31 | 2016-05-31 | Rensselaer Polytech Inst | 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides |
AR035513A1 (es) * | 2000-12-23 | 2004-06-02 | Hoffmann La Roche | Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos |
DE10146867A1 (de) | 2001-09-24 | 2003-04-24 | Bayer Ag | Tetrahydroisochinoline |
AU2003249713A1 (en) * | 2002-07-03 | 2004-01-23 | Axys Pharmaceuticals, Inc. | 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
ES2294475T3 (es) * | 2003-03-07 | 2008-04-01 | Eli Lilly And Company | Derivados de nicotinamida g-sustituidos como antagonistas de receptores de opioides. |
GB0305575D0 (en) | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
US7056930B2 (en) * | 2003-04-14 | 2006-06-06 | Pfizer Inc. | 2-Azabicyclo[3.3.1]nonane derivatives |
NZ546834A (en) * | 2003-10-01 | 2010-03-26 | Adolor Corp | Spirocyclic heterocyclic derivatives and methods of their use |
ES2257168B1 (es) * | 2004-08-18 | 2007-06-01 | Laboratorios Del Dr Esteve, S.A. | Ligandos del receptor 5-ht7. |
WO2006045096A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
US8163744B2 (en) | 2005-03-18 | 2012-04-24 | Nexuspharma, Inc. | Tetrahydro-isoquinolin-1-ones for the treatment of cancer |
US8101580B2 (en) * | 2005-04-21 | 2012-01-24 | Astellas Pharma Inc. | Therapeutic agent for irritable bowel syndrome |
RU2302417C1 (ru) | 2006-03-14 | 2007-07-10 | Иващенко Андрей Александрович | 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека |
RU2303597C1 (ru) * | 2006-05-12 | 2007-07-27 | Иващенко Андрей Александрович | Фармацевтическая композиция, способы ее получения и применения |
WO2008034039A2 (en) * | 2006-09-15 | 2008-03-20 | Nexuspharma Inc. | Novel tetrahydro-isoquinolines |
WO2008112715A2 (en) * | 2007-03-12 | 2008-09-18 | Vm Discovery Inc. | Novel agents of calcium ion channel modulators |
WO2008131779A1 (en) * | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
PT2149560E (pt) * | 2007-05-22 | 2015-07-13 | Astellas Pharma Inc | Composto de tetra-hidroisoquinolina substituído na posição 1 |
WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
-
2008
- 2008-05-23 TW TW097119184A patent/TWI425945B/zh not_active IP Right Cessation
- 2008-05-26 US US12/600,894 patent/US8486970B2/en not_active Expired - Fee Related
- 2008-05-26 JP JP2009516311A patent/JP5336359B2/ja not_active Expired - Fee Related
- 2008-05-26 PT PT87646543T patent/PT2149561E/pt unknown
- 2008-05-26 KR KR1020167033484A patent/KR101830566B1/ko active IP Right Grant
- 2008-05-26 DK DK08764654.3T patent/DK2149561T3/en active
- 2008-05-26 ES ES08764654.3T patent/ES2558677T3/es active Active
- 2008-05-26 PL PL08764654T patent/PL2149561T3/pl unknown
- 2008-05-26 CA CA2688326A patent/CA2688326C/en not_active Expired - Fee Related
- 2008-05-26 RU RU2009148507/04A patent/RU2479578C2/ru active
- 2008-05-26 AU AU2008255815A patent/AU2008255815B2/en not_active Ceased
- 2008-05-26 SI SI200831545T patent/SI2149561T1/sl unknown
- 2008-05-26 KR KR1020097027024A patent/KR101580298B1/ko active IP Right Grant
- 2008-05-26 EP EP08764654.3A patent/EP2149561B1/en active Active
- 2008-05-26 MX MX2009012779A patent/MX2009012779A/es active IP Right Grant
- 2008-05-26 BR BRPI0812359-4A2A patent/BRPI0812359A2/pt active Search and Examination
- 2008-05-26 KR KR1020157019531A patent/KR101682638B1/ko active Application Filing
- 2008-05-26 RS RS20150826A patent/RS54429B1/en unknown
- 2008-05-26 WO PCT/JP2008/059621 patent/WO2008146774A1/ja active Application Filing
- 2008-05-26 CN CN2008800139534A patent/CN101668747B/zh not_active Expired - Fee Related
- 2008-05-26 HU HUE08764654A patent/HUE026316T2/en unknown
-
2009
- 2009-11-20 ZA ZA2009/08220A patent/ZA200908220B/en unknown
- 2009-11-24 IL IL202301A patent/IL202301A/en active IP Right Grant
-
2013
- 2013-07-15 US US13/942,158 patent/US9150541B2/en not_active Expired - Fee Related
-
2015
- 2015-08-26 US US14/836,228 patent/US9526719B2/en active Active
- 2015-12-07 HR HRP20151336TT patent/HRP20151336T1/hr unknown
- 2015-12-08 CY CY20151101112T patent/CY1117004T1/el unknown
-
2016
- 2016-11-14 US US15/350,427 patent/US10016410B2/en not_active Expired - Fee Related
-
2018
- 2018-07-05 US US16/027,988 patent/US10532048B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117004T1 (el) | Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτου | |
CY1121043T1 (el) | Θεραπευτικες ενωσεις | |
CY1117995T1 (el) | Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
CY1113352T1 (el) | Ενωση σπειρο-δακτυλιου και χρηση αυτης για ιατρικους σκοπους | |
CY1119405T1 (el) | Ενωση για την αναστολη ενζυμων | |
EA200601686A1 (ru) | Замещенные производные морфолина и тиоморфолина | |
CY1119248T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες | |
CL2012000033A1 (es) | Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer. | |
CR11518A (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
CY1116150T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
NI201000041A (es) | Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma. | |
EA200900613A1 (ru) | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз | |
CY1111087T1 (el) | Παραγωγα 5-(βενζ-(ζ)-υλιδενο)-θειαζολιδιν-4-ονης ως ανοσοκατασταλτικοι παραγοντες | |
EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
AR077478A2 (es) | Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos | |
CY1114799T1 (el) | Παραγωγα τετραϋδροκινολινης για τη θεραπεια διαταραχων μετατραυματικου στρες | |
ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
CY1111789T1 (el) | Ετεροκυκλικες ενωσεις | |
ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
CY1113439T1 (el) | Ενωση αζολιου | |
ECSP099442A (es) | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona | |
EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы | |
CY1115903T1 (el) | Φλουρμπιπροφαινη και μυοχαλαρωτικοι συνδυασμοι | |
CY1113171T1 (el) | Αντιφλεγμονωδεις παραγοντες |